EVOK

시간 외 거래: 4.64

Evoke Pharma Inc (EVOK)

개요 뉴스 가격 이력 Financials 토론 예측 주식 분할

Relative Volume:

Evoke Pharma Inc Stock (EVOK) Company Profile

Evoke Pharma Inc

Healthcare (1174)

858-345-1494

420 STEVENS AVENUE, SOLANA BEACH, CA

최신 SEC 제출 서류

EVOK's Discussions on Twitter

EVOK을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
EVOK Evoke Pharma Inc	4.64	6.90M	5.18M	-7.79M	-4.99M	-2.33
ZTS Zoetis Inc	163.31	73.68B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.46	42.77B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	13.26	42.04B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	21.24	24.07B	16.77B	-959.00M	1.37B	-0.85
VTRS Viatris Inc	12.28	14.66B	15.05B	-883.30M	1.89B	-0.74

Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2020-06-22	업그레이드	H.C. Wainwright	Neutral → Buy
2019-03-05	다운그레이드	H.C. Wainwright	Buy → Neutral
2018-03-08	재확인	B. Riley FBR, Inc.	Buy
2017-10-19	재개	FBR & Co.	Buy
2017-03-16	재확인	Rodman & Renshaw	Buy
2017-01-30	업그레이드	Laidlaw	Neutral → Buy
2017-01-05	업그레이드	Rodman & Renshaw	Neutral → Buy
2016-12-23	재확인	Rodman & Renshaw	Neutral
2016-07-19	재확인	FBR Capital	Outperform
2016-07-19	다운그레이드	Noble Financial	Buy → Hold
2016-07-18	다운그레이드	Rodman & Renshaw	Buy → Neutral
2016-03-16	개시	Northland Capital	Outperform
2016-03-14	재확인	Ascendiant Capital Markets	Buy
2016-02-17	재개	FBR Capital	Outperform
2014-12-03	재확인	MLV & Co	Buy
2014-11-07	개시	MLV & Co	Buy
2014-04-22	개시	Laidlaw	Buy
2013-11-19	개시	Aegis Capital	Buy

Evoke Pharma Inc 주식(EVOK)의 최신 뉴스

Evoke Pharma Inc (EVOK) 재무 분석

Evoke Pharma Inc (EVOK)

Evoke Pharma Inc Stock (EVOK) Company Profile

EVOK을(를) 다른 주식과 비교

Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades

Evoke Pharma Inc 주식(EVOK)의 최신 뉴스

Head to Head Contrast: Northwest Biotherapeutics (OTCMKTS:NWBO) vs. Evoke Pharma (NASDAQ:EVOK) - Defense World

Thinking about buying stock in Agile Therapeutics, Evoke Pharma, Warner Bros Discovery, Nkarta, or Sky Harbour? - Marketscreener.com

Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World

Financial Survey: Evoke Pharma (NASDAQ:EVOK) and Geron (NASDAQ:GERN) - Defense World

StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World

Siga Technologies (SIGA) Stock Surges Over 5% Amid Market Activi - GuruFocus.com

Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail

Adeia Enters into Multi-Year IP License Agreement with Canon - The Manila Times

Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, - openPR

Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends - GlobeNewswire

Gastroparesis Treatment Market Generated Opportunities, - openPR

Target Corp (TGT-N) QuotePress Release - The Globe and Mail

Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com - Defense World

EVOK (Evoke Pharma) 5-Day RSI : 40.08 (As of Dec. 05, 2024) - GuruFocus.com

EVOK (Evoke Pharma) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com

Gray Television (GTN-N) QuotePress Release - The Globe and Mail

Mercadolibre Inc (MELI-Q) QuotePress Release - The Globe and Mail

Paramount Global Cl B (PARA-Q) QuotePress Release - The Globe and Mail

Comfort Systems USA (FIX-N) QuotePress Release - The Globe and Mail

Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® - GlobeNewswire

TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail

TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail

EVOK (Evoke Pharma) 5-Day RSI : 34.66 (As of Nov. 28, 2024) - GuruFocus.com

Dell Technologies Inc (DELL-N) QuotePress Release - The Globe and Mail

Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve

First Solar Inc (FSLR-Q) QuotePress Release - The Globe and Mail

Mesenchymal Stem Cells (MSC) Market Set to Surpass USD 9.72 - GlobeNewswire

Diabetic Gastroparesis Pipeline 2024: Clinical Trials - openPR

EVOK (Evoke Pharma) Total Assets : $14.15 Mil (As of Sep. 2024) - GuruFocus.com

Diabetic Gastroparesis Treatment Market: Global Size, Share, - openPR

Altium Capital Management LP Increases Stake in Evoke Pharma Inc - GuruFocus.com

Canopy Growth (CGC) Stock Dives Amid Financial Struggles and Ind - GuruFocus.com

CRON Experiences Significant Stock Dip Amid Market Volatility - GuruFocus.com

Aurora Cannabis (ACB) Shares Drop Amidst Financial Performance C - GuruFocus.com

Nasal Drug Delivery Technology Market Breakthrough in Patient Care, Projected Market Growth to USD 7.8 Billion by 2031Market Research Intellect - The Malaysian Reserve

By popular demand: SiGMA Europe launches fourth shed - GlobeNewswire Inc.

Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com - Defense World

Evoke Pharma Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Evoke Pharma earnings missed by $0.95, revenue fell short of estimates - Investing.com UK

(EVOK) Trading Advice - Stock Traders Daily

BlackLine Announces the Planned Retirement of Chief Financial Officer and Names Successor - The Manila Times

Evoke Pharma Reports Q3 2024 Financial Results - TipRanks

Canopy Growth (CGC) Stock Surges 5.2% Amid Industry Movement - GuruFocus.com

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results - The Manila Times

Nantahala Capital Management's Strategic Acquisition in Evoke Ph - GuruFocus.com

Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve

Ironwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive A - GuruFocus.com

Evoke Pharma Inc (EVOK) 재무 분석

매출

순이익

현금흐름

주당 순 이익

EVOK과 유사한 종목